MAIA Biotechnology (MAIA) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed NeOnc Technologies (NTHI) over the past year, losing 36.5% versus a loss of 76.8%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $75.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | NTHI |
|---|---|---|
| Share price | $1.22 | $2.78 |
| Market cap | $75.33M | $80.08M |
| 1-day change | +6.09% | +9.88% |
| YTD return | -24.84% | -66.38% |
| 1-year return | -36.46% | -76.79% |
| Forward P/E | 1.10 | — |
| EPS (TTM) | $-0.62 | $-2.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $12.09 |
| 52-week low | $0.87 | $2.50 |
| Distance from 52-week high | -61.76% | -77.01% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +883.61% | +511.51% |
| Average volume | 527.89K | 195.17K |
| Shares outstanding | 61.74M | 28.81M |
| Employees | 13 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed NTHI by 40.3 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
MAIA vs NTHI FAQ
Which is bigger, MAIA Biotechnology or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $75.33M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, MAIA or NTHI?
MAIA returned -36.46% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.